A Single Dose of Pegylated Leridistim Significantly Improves Neutrophil Recovery in Sublethally Irradiated Rhesus Macaques

University of Maryland, Baltimore, Baltimore, Maryland, United States
Stem Cells (Impact Factor: 6.52). 02/2001; 19(6):514-21. DOI: 10.1634/stemcells.19-6-514
Source: PubMed


Leridistim, a member of the myelopoietin family of dual receptor agonists that binds interleukin-3 and G-CSF receptors, has been shown to enhance hematopoietic activity in rhesus monkeys above that observed with either cytokine alone or in combination. This study demonstrated the ability of a pegylated form of leridistim (peg-leridistim), administered s.c., as a single- or two-dose regimen separated by 4 or 7 days, to significantly improve neutrophil recovery following radiation-induced myelosuppression. Rhesus macaques were total body x-irradiated (250 kVp, TBI) to 600 cGy. Following TBI, two groups received peg-leridistim (n = 5) or leridistim (n = 4) at a dose of 600 microg/kg on day 1, while two other groups (both n = 4) received peg-leridistim at 200 microg/kg on day 1 and day 4, or day 1 and day 7. The irradiation controls (n = 7) received 0.1% autologous serum for 18 days. All peg-leridistim treatment schedules significantly improved all neutrophil-related parameters following TBI as compared with nontreated controls and were equivalent in effect when compared among themselves. Administration of a single high dose or two separate lower doses of peg-leridistim significantly improved neutrophil regeneration, in a manner equal to that of conventional daily or abbreviated every-other-day administration of leridistim in this nonhuman primate model of severe myelosuppression.

Download full-text


Available from: Thomas J Macvittie, Dec 11, 2014
  • Source
    • "Rhesus macaques irradiated with 6 Gy of X-rays and subsequently given the IL-3 and granulocyte colony-stimulating factor (G-CSF) receptor agonists leridistim and pegylated leridistim, showed significant improvement of all neutrophil-related parameters when compared to the non-irradiated controls (Farese et al., 2001). This indicated recovery from severe myelosuppression (Farese et al., 2001). Future studies may reveal additional cytokines that will further increase the effectiveness of this treatment in order to optimize protection and accelerate the recovery of irradiated organisms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: For individuals traveling in space, exposure to space radiation is unavoidable. Since adequate shielding against radiation exposure is not practical, other strategies for protecting the astronauts must be developed. Radiation is also an important therapeutic and diagnostic tool, and evidence from the clinical and experimental settings now shows a firm connection between radiation exposure and changes in cytokine and chemokine levels. These small proteins can be pro- or anti-inflammatory in nature and the balance between those two effects can be altered easily because of exogenous stresses such as radiation. The challenge to identify a common perpetrator, however, lies in the fact that the cytokines that are produced vary based on radiation dose, type of radiation, and the cell types that are exposed. Based on current knowledge, special treatments have successfully been designed by implementing administration of proteins, antibodies, and drugs that counteract some of the harmful effects of radiation. Although these treatments show promising results in animal studies, it has been difficult to transfer those practices to the human situation. Further understanding of the mechanisms by which cytokines are triggered through radiation exposure and how those proteins interact with one another may permit the generation of novel strategies for radiation protection from the damaging effects of radiation. Here, we review evidence for the connection between cytokines and the radiation response and speculate on strategies by which modulating cytokine responses may protect astronauts against the detrimental effects of ionizing radiations.
    Full-text · Article · Dec 2007 · Advances in Space Research
  • Source
    • "n radiation myelosuppressed non - human primates better than IL - 3 or G - CSF ( Farese et al . , 2001b ) . The administration of a single high dose of pegylated leridistim significantly improved neutrophil regeneration , in a manner equal to that of conventional daily or every other day administration of leridistim in non - human primate models ( Farese et al . , 2001c ) . Progenipoietin combines Flt - 3 ( an early acting hemato - poietic cytokine ) and G - CSF ligands , and activates cells bearing Flt - 3 and G - CSF surface receptors ( Fry et al . , 2002 ; Streeter et al . , 2001 ) . The preclinical data indicate that the chimeric growth factor receptor agonists are potent stim - ulators of hematopo"
    [Show abstract] [Hide abstract]
    ABSTRACT: Cytokines and growth factors are growing groups of proteins that are responsible for the communication between cells of the immune system, hematopoietic cells, and other cell types. The cloning and large-scale production in a recombinant form of these agents in pharmacological quantities permitted investigations aimed at assessing the benefit they may provide in preserving and restoring functions of tissues compromised by irradiation. We have extensively examined past investigations which suggest that some cytokines and growth factors protect animals from radiation lethality when given prior to or after irradiation, and even in untreated animals, these cytokines serve in innate defenses against external stimuli. In contrast, some cytokines given before irradiation sensitize the animals to radiation lethality. Unfortunately, due to their adverse side effects, these cytokines were not found suitable as radioprotectors. Recent studies suggest that new approaches may bring cytokines and growth factors in clinic for radiation injury. The information and insight gained about therapeutic potential of cytokine manipulation will allow for more rational design of treatment protocols.
    Full-text · Article · May 2005 · Experimental and Molecular Pathology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the terrorist attack of September 11, 2001, preparation by the health care system for an act of terrorism has been mandated by leaders of governments. Scenarios for terrorist acts involving radioactive material have been identified, and approaches to management (based on past experience from atomic weapons detonations and radiation accidents) have been developed. Because of their experience in managing patients with profound cytopenia and/or marrow aplasia, hematologists will be asked to play a significant role in evaluating and treating victims of mass accidental or deliberate exposure to radiation. This review provides a framework for understanding how radiation levels are quantified, how radiation alters the function of hematopoietic (and nonhematopoietic) cells and tissues, and how victims receiving a significant radiation dose can be identified and managed. In Section I, Dr. Nicholas Dainiak reviews four components of the Acute Radiation Syndrome: the hematopoietic, neurovascular, gastrointestinal and cutaneous subsyndromes. Clinical signs and symptoms are discussed for exposed individuals at the time of initial presentation (the prodromal phase) and during their course of disease (the manifest illness). In Section II, he presents clinical and laboratory methods to assess radiation doses, including time to onset and severity of vomiting, rate of decline in absolute blood lymphocyte count and the appearance of chromosome aberrations such as dicentrics and ring forms. Potential scenarios of a radiation terrorist event are reviewed, and methods for initial clinical assessment, triage, and early management of the acute radiation syndrome and its component subsyndromes are summarized. In Section III, Dr. Jamie Waselenko reviews the hematopoietic syndrome, and presents guidelines for the use of cytokine therapy, antibiotics, and supportive care that have been developed by the Strategic National Pharmaceutical Stockpile Working Group. Results of preclinical and clinical growth factor therapy studies with G-CSF, GM-CSF, pegylated G-CSF, SCF, and IL-3 are summarized. When and how potassium iodide should be used after exposure to radioiodines is also reviewed. In Section IV, Dr. James Armitage describes a narrow "window" of 7 to 10 Gy where therapy with stem cell transplantation may be appropriate. Victims who are candidates for allotransplantation should not have major trauma or significant injury to other (nonhematopoietic) tissues. Rarely, victims may have an identical sibling or autologous stored marrow or blood stem cells, in which case the threshold for transplantation is 4 Gy. In Section V, Dr. Thomas MacVittie describes new directions for therapy, using cytokines such as IL-7, keratinocyte growth factor, and FLT-3. The potential for combinations of cytokines to enhance hematopoietic recovery is also reviewed.
    Full-text · Article · Feb 2003 · Hematology
Show more